CAPR

Capricor Therapeutics Inc

11.22

Nov 11 • 3:59 PM ET +2.35 (26.49%)

11.03

Aftermarket • 7:59 PM ET -0.19 (-1.69%)

Healthcare Biotechnology USA Small NASD

Today, 8:31 PMJonesTrading Buy upgrade lifts Capricor 26% ahead of Nov. 22 FDA decision

Peers: SRPT SLDB WVE DYN EWTX MESO PEPG TNYA BCDA LGVN

| Held by: XBI VTI IWM VXF IWO VTWO VHT LABU ITOT VTWG

Scroll to Statements

Index	RUT
Market Cap	652.32M
Enterprise Value	546.97M
Income	-147.50M
Sales	0.00M
Book/sh	3.61
Cash/sh	3.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	231
IPO	Jun 20, 2002

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.11
P/C	3.30
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.77
Current Ratio	6.77
Debt/Eq	0.44
LT Debt/Eq	0.43
Option/Short	Yes / Yes

EPS (ttm)	-2.65
EPS next Y	-1.49
EPS next Q	-0.37
EPS this Y	-4.97%
EPS next Y	37.19%
EPS next 5Y	47.99%
EPS past 3/5Y	-24.12% -20.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	-47.08%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-36.52%
Sales Q/Q	-
Earnings	Nov 10 AMC
EPS/Sales Surpr.	-66.36% -100.00%

Insider Own	9.44%
Insider Trans	-0.90%
Inst Own	72.95%
Inst Trans	12.24%
ROA	-64.58%
ROE	-100.47%
ROIC	-49.09%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	51.42%
SMA50	38.71%
SMA200	-44.35%
Trades

Shs Outstand	58.14M
Shs Float	52.65M
Short Float	35.64%
Short Ratio	3.12
Short Interest	18.77M
52W High	40.37 -72.21%
52W Low	2.96 279.05%
Volatility	14.46% 10.73%
ATR (14)	0.92
RSI (14)	69.35
Beta	0.73
Rel Volume	1.67
Avg Volume	6.01M
Volume	10,068,973

Perf Week	25.78%
Perf Month	63.08%
Perf Quarter	166.51%
Perf Half Y	-63.01%
Perf YTD	-61.12%
Perf Year	80.97%
Perf 3Y	300.71%
Perf 5Y	223.34%
Perf 10Y	-58.75%
Recom	1.89
Target Price	26.67
Prev Close	8.87
Price	11.22
Change %	26.49%

Consensus

Buy

Avg. Price Target

$26.67

Implied Upside

+137.7%

Analysts10incl. previous ratings

Rating Distribution5 Buy · 5 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Today	Upgrade	JJones Trading	Hold → Buy	$25	+122.8%
Sep 14, 2026	Upgrade	RB. Riley Securities	Neutral → Buy	$21	+87.2%
Sep 01, 2026	Upgrade	PPiper Sandler	Neutral → Overweight	$25	+122.8%
Aug 25, 2026	Upgrade	OOppenheimer	Perform → Outperform	$54	+381.3%
Aug 14, 2026	Upgrade	CCantor Fitzgerald	Neutral → Overweight	$28	+149.6%
Jul 30, 2026	Downgrade	PPiper Sandler	Overweight → Neutral	$2	-82.2%
Jul 30, 2026	Downgrade	OOppenheimer	Outperform → Perform
Jul 30, 2026	Downgrade	MMaxim Group	Buy → Hold
Jul 30, 2026	Downgrade	LLadenburg Thalmann	Buy → Neutral
Jul 30, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral
Jul 30, 2026	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$3.50	-68.8%
Jul 28, 2026	Downgrade	AAlliance Global Partners	Buy → Neutral	$7	-37.6%
Jul 27, 2026	Downgrade	RRoth Capital	Buy → Neutral	$7	-37.6%
Jul 27, 2026	Downgrade	RB. Riley Securities	Buy → Neutral	$10	-10.9%
Jun 30, 2025	Initiated	AAlliance Global Partners	Buy	$20	+78.3%
Jun 26, 2025	Initiated	RB. Riley Securities	Buy	$21	+87.2%
May 20, 2025	Initiated	RRoth Capital	Buy	$31	+176.3%
Oct 21, 2024	Initiated	PPiper Sandler	Overweight	$35	+211.9%
May 17, 2024	Initiated	OOppenheimer	Outperform	$14	+24.8%
Jan 05, 2024	Initiated	CCantor Fitzgerald	Overweight	$8	-28.7%

Today 12:42PM	CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month (Stocktwits) +26.49%
Nov-10-26 06:56PM	CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review (Stocktwits) -9.95%
05:47PM	Capricor Misses As Pre-Launch Spending Climbs; Data Package Is Rebuilt, But The November 22 FDA Decision Now Rests On A Narrower Indication (Earnings Whispers)
04:34PM	Capricor: Q3 Earnings Snapshot (Associated Press)
04:05PM	Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
06:21AM	Loading…
06:21AM	CAPR Stock Edges Higher Ahead Of Q3 Earnings, But Retails Attention Remains Firmly Fixed On Nov. 22 FDA Decision For Deramiocel (Stocktwits)
05:20AM	US Stock Futures Mixed As Investors Await CPI Data AMD, CRWV, RKLB Stocks In Focus (Stocktwits)
Nov-09-26 03:12PM	CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision (Stocktwits) +9.44%
09:00AM	Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology (GlobeNewswire)
Nov-04-26 02:33PM	Capricor's Q3 Report Must Show Whether Its Narrower FDA Path For Deramiocel Is Holding (Earnings Whispers) +8.25%
Nov-03-26 04:57PM	CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel (Stocktwits) +13.81%
09:00AM	Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10 (GlobeNewswire)
Nov-02-26 05:36AM	FDA Decision Watch: Regeneron And Roches Autoimmune Drugs, Capricors DMD Therapy In Spotlight (Stocktwits) +13.48%
Nov-01-26 11:21PM	CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval Tea Leaves In Capricors Launch Team Hiring (Stocktwits)
Oct-21-26 03:52PM	CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears (Stocktwits) -11.04%
07:30PM	Loading…
Oct-07-26 07:30PM	CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision (Stocktwits)
Oct-05-26 11:59AM	Capricors DMD Therapy Shows 76% Slower Upper-Limb Decline This Analyst Expects A Complete Response Letter In November (Stocktwits) -13.07%
09:00AM	Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress (GlobeNewswire)
Sep-30-26 08:02PM	CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan (Stocktwits) +10.50% -5.60%
Sep-29-26 09:24PM	Why Did CAPR Stock Jump 20% After-Hours Today? (Stocktwits)
Sep-28-26 02:10AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Sep-21-26 05:06PM	These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
Sep-17-26 08:30AM	Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress (GlobeNewswire) +10.05%
Sep-11-26 03:15PM	Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors Who Suffered Losses to Seek a Leadership Role Before September 28, 2026 (Newsfile)
Sep-09-26 08:40AM	LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation (Business Wire)
Sep-01-26 02:15PM	Kaplan Fox Urges Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026 (Newsfile)
06:55AM	Capricor Therapeutics shares rise 2.5% following August FDA update (InvestorsHub)
06:52AM	Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision (Stocktwits)
Aug-27-26 03:00PM	SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data Retail Eyes Monumental Comeback (Stocktwits) +7.48%
Aug-24-26 05:02PM	CAPR Stock Climbs On FDAs Three-Month Deramiocel Extension HC Wainwright Sticks To Neutral, Flags High Rejection Risk (Stocktwits) +8.11% +21.91%
10:33AM	Loading…
10:33AM	Why Is CAPR Stock Rising Today? (Stocktwits)
10:05AM	Capricor Therapeutics Deramiocel PDUFA Date Extended to November as FDA Reviews BLA Amendment (InvestorsHub)
09:25AM	Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA (GlobeNewswire)
07:30AM	FDA extends review of Capricor cell therapy; Pain drug startup to go public (BioPharma Dive)
Aug-21-26 06:48PM	CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel (Stocktwits) -7.97%
11:00AM	Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy (Stocktwits)
05:30AM	Shareholder pressures Capricor; Lilly dives deeper into vaccines (BioPharma Dive)
Aug-17-26 01:17AM	Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom (Stocktwits) +12.03%
Aug-14-26 09:15AM	Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors with Losses to Contact the Firm Before September 28, 2026 (Newsfile) +57.96%
06:18AM	CAPR Stock Explodes Premarket: Cantor Flips Bullish, Sees 278% Upside On Deramiocel FDA Path (Stocktwits)
05:28AM	Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers (BioPharma Dive)
01:03AM	Capricor Therapeutics Inc (CAPR) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback and ... (GuruFocus.com)
Aug-13-26 07:32PM	CAPR Stock Surges 67% After-Hours Is There Still A Path Forward For Deramiocel? (Stocktwits)
05:00PM	Capricor: Q2 Earnings Snapshot (Associated Press)
04:05PM	Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
04:12AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-11-26 07:07AM	CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop (PR Newswire)
Aug-10-26 08:30AM	Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13 (GlobeNewswire) -5.87%
Aug-06-26 04:09PM	Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (CAPR) Who Suffered Losses to Contact the Firm Before September 28, 2026 (Newsfile) +6.36%
Aug-05-26 04:08PM	Kaplan Fox Urges Investors of Capricor Therapeutics, Inc. (CAPR) with Significant Losses to Seek a Leadership Role Before September 28, 2026 (Newsfile) -5.76%
Aug-03-26 05:26PM	MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus These FDA Decisions Could Shape August Trading (Stocktwits) +9.09%
07:30AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights CAPR (Business Wire)
Jul-31-26 01:42PM	CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy (Stocktwits) -8.11%
Jul-30-26 11:32PM	Why did CAPR, LKQ, PSKY Stocks Plunge To 52-Week Lows Today? (Stocktwits) -36.23%
10:55AM	Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel (Business Wire)
09:38AM	Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls (The Fly)
09:30AM	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel (GlobeNewswire)
07:58AM	Capricors FDA Fate Divides Wall Street And Investors: One Analyst Sees A $2 Stock But Retail Holds Out Hope (Stocktwits)
Jul-29-26 11:07PM	CAPR Stock Eyes Worst Week Ever After FDA Panel Blow To Deramiocel Retail Bulls Still See A Path To Approval (Stocktwits)
06:25PM	FDA Advisory Panel Votes Against Capricor Therapy (The Wall Street Journal)
04:24PM	Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy Experts And Investors Weigh In (Stocktwits)
12:20PM	Capricors DMD Therapy Gets Lancet Backing Ahead Of August FDA Showdown CEO Says Publication Reinforce Our Confidence For Approval (Stocktwits)
10:05AM	The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-28-26 12:07PM	This Analyst Slashed CAPR Stocks Target By 86% But, Retail Bulls Say Setup Offers An Attractive Risk-Reward (Stocktwits) -6.08%
Jul-27-26 10:38PM	CAPR Stock Eyes Worst Month In 9 Years On FDA Doubts Pharma Bro Shkreli Piles On, But Retail Turns More Bullish Than Ever (Stocktwits) -64.49%
03:42PM	CAPR Stock On Track For Worst Day Ever Analysts Divided On Deramiocels Approval Probability After FDA Documents Paint Ugly Picture (Stocktwits)
11:39AM	Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review CAPR Stock Plummets After Agency Released Briefing Document (Stocktwits)
11:00AM	Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel (GlobeNewswire)
10:50AM	Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy (Proactive)
09:48AM	CAPR Stock Is Crashing Today FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote (Stocktwits)
09:43AM	Capricor Therapeutics shares plunge after FDA releases briefing documents (InvestorsHub)
07:00AM	FDA scientists question Capricor data; Legend CEO steps down (BioPharma Dive)
Jul-24-26 08:30PM	FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions (Stocktwits)
Jul-23-26 08:09PM	CAPR Stock On Track To Clock Weekly Gains Ahead Of Critical FDA Panel Retail Deems It A Binary Event (Stocktwits)
Jul-22-26 06:52AM	CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricors DMD Therapy Faces FDA Panel Review Next Week, Retail Sees 'Excellent Opportunity' (Stocktwits)
Jun-30-26 12:15AM	CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review (Stocktwits)
Jun-26-26 11:58AM	Capricors Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch CAPR Stock Slides 11% (Stocktwits) -13.03%
10:02AM	Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
09:05AM	Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference (GlobeNewswire)
Jun-17-26 10:24AM	All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement CAPR Stock Jumps 6% (Stocktwits) +7.29%
Jun-08-26 09:25AM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-13-26 01:02AM	Capricor Therapeutics Inc (CAPR) Q1 2026 Earnings Call Highlights: Strong Cash Position Amid ... (GuruFocus.com)
May-12-26 04:21PM	Capricor: Q1 Earnings Snapshot (Associated Press)
04:05PM	Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive) +5.00%
May-04-26 04:05PM	Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 (GlobeNewswire) +8.38%
Apr-22-26 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire)
Mar-25-26 07:30AM	Caprock Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at Destiny (TMX Newsfile)
Mar-23-26 10:50AM	Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp. (TMX Newsfile)
Mar-12-26 11:07PM	Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... (GuruFocus.com) -8.74%
04:27PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
09:00AM	Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-10-26 10:47AM	Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review (Benzinga) +9.04%
09:25AM	Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA (GlobeNewswire)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +9.78%
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:30AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 (GlobeNewswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krasney Karen	EVP, GENERAL COUNSEL	Jun 25 '26	Option Exercise	3.18	24,100	76,638	54,647	Jun 29 09:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 25 '26	Sale	30.38	24,100	732,158	30,547	Jun 29 09:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 25 '26	Option Exercise	3.18	24,100	76,638	35,323	Jun 29 09:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 25 '26	Sale	30.38	24,100	732,158	11,223	Jun 29 09:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 22 '26	Option Exercise	3.18	500	1,590	31,047	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 24 '26	Option Exercise	3.18	400	1,272	30,947	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 22 '26	Sale	30.00	500	15,000	30,547	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 24 '26	Sale	30.00	400	12,000	30,547	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 22 '26	Option Exercise	3.18	500	1,590	11,723	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 24 '26	Option Exercise	3.18	400	1,272	11,623	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 22 '26	Sale	30.00	500	15,000	11,223	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 24 '26	Sale	30.00	400	12,000	11,223	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 18 '26	Option Exercise	1.39	3,000	4,170	11,223	May 19 04:15 PM
Musket David B	Director	May 19 '26	Proposed Sale	27.00	88,788	2,397,256		May 19 11:40 AM
Litvack Frank	Director	May 13 '26	Option Exercise	1.39	3,937	5,472	133,776	May 14 05:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	May 01 '26	Option Exercise	3.18	25,000	79,500	55,547	May 04 04:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	May 01 '26	Sale	31.70	25,000	792,548	30,547	May 04 04:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 01 '26	Option Exercise	3.18	25,000	79,500	33,223	May 04 04:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 01 '26	Sale	31.70	25,000	792,540	8,223	May 04 04:30 PM
Sabar Karimah Es	Director	Apr 02 '26	Option Exercise	3.18	7,529	23,942	7,529	Apr 03 05:00 PM
Sabar Karimah Es	Director	Apr 02 '26	Sale	32.00	7,529	240,928	0	Apr 03 05:00 PM
Karimah Es Sabar	Director	Apr 02 '26	Proposed Sale	30.12	7,529	226,773		Apr 02 04:24 PM
Krasney Karen	EVP, GENERAL COUNSEL	Mar 31 '26	Option Exercise	3.61	25,000	90,293	55,547	Apr 01 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Mar 31 '26	Sale	30.12	25,000	752,935	30,547	Apr 01 08:00 PM
Sabar Karimah Es	Director	Mar 31 '26	Option Exercise	4.86	61,265	297,748	61,265	Apr 01 08:00 PM
Sabar Karimah Es	Director	Apr 01 '26	Option Exercise	4.86	53,735	261,152	53,735	Apr 01 08:00 PM
Sabar Karimah Es	Director	Mar 31 '26	Sale	30.17	61,265	1,848,243	0	Apr 01 08:00 PM
Sabar Karimah Es	Director	Apr 01 '26	Sale	31.03	53,735	1,667,225	0	Apr 01 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Mar 31 '26	Option Exercise	3.18	25,000	79,500	33,223	Apr 01 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Mar 31 '26	Sale	30.13	25,000	753,152	8,223	Apr 01 08:00 PM
Karen Krasney	Officer	Mar 31 '26	Proposed Sale	27.77	75,000	2,082,750		Mar 31 04:23 PM
ANTHONY BERGMANN	Officer	Mar 31 '26	Proposed Sale	27.77	75,000	2,082,750		Mar 31 04:23 PM
Karimah Es Sabar	Director	Mar 31 '26	Proposed Sale	27.77	115,000	3,193,550		Mar 31 04:22 PM
Krasney Karen	EVP, GENERAL COUNSEL	Dec 30 '25	Option Exercise	1.39	2,500	3,475	30,547	Mar 27 07:15 PM
DUNBAR GEORGE W JR	Director	Dec 19 '25	Option Exercise	1.39	3,000	4,170	14,306	Dec 23 02:55 PM

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy ("DMD"), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

M.D.Dr. Frank Isaac Litvack FACC

Co-FounderDr. Linda Marban Ph.D.

CFO & Corporate TreasurerMr. Anthony J. Bergmann M.B.A.

J.D.Ms. Karen G. Krasney Esq.

Chief Operating & Science OfficerDr. Kristi A. H. Elliott Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

CAPR

Capricor Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.